Trials / Sponsors / National Cancer Institute (NCI)
National Cancer Institute (NCI)
NIH · 3,536 registered clinical trials — 266 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cance Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 1 / Phase 2 | 2026-12-21 |
| Recruiting | Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients Wit Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8 | Phase 2 | 2026-11-24 |
| Not Yet Recruiting | A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Opt Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | 2026-10-30 |
| Not Yet Recruiting | Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukem Acute Myeloid Leukemia | Phase 2 | 2026-10-14 |
| Recruiting | Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in th Burkitt Lymphoma, Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 1 / Phase 2 | 2026-10-13 |
| Recruiting | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Ca Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | 2026-10-09 |
| Not Yet Recruiting | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk B Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Phase 2 | 2026-10-06 |
| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 1 | 2026-10-05 |
| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 1 | 2026-10-01 |
| Not Yet Recruiting | Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxoru Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma | Phase 2 | 2026-09-10 |
| Recruiting | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymp Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Phase 2 | 2026-09-08 |
| Recruiting | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma | Phase 2 | 2026-08-21 |
| Not Yet Recruiting | Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CH Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma | Phase 1 | 2026-08-20 |
| Recruiting | Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | 2026-08-14 |
| Recruiting | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non- Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 1 / Phase 2 | 2026-08-07 |
| Not Yet Recruiting | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded t Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma | Phase 1 / Phase 2 | 2026-07-30 |
| Not Yet Recruiting | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Acute Myeloid Leukemia | Phase 2 | 2026-07-17 |
| Not Yet Recruiting | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy Wi Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8 | Phase 3 | 2026-07-07 |
| Not Yet Recruiting | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hy Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | Phase 2 | 2026-07-06 |
| Not Yet Recruiting | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Phase 2 | 2026-07-01 |
| Not Yet Recruiting | Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patie Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma | Phase 1 | 2026-06-28 |
| Recruiting | Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia | Phase 1 / Phase 2 | 2026-06-27 |
| Not Yet Recruiting | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treat Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2026-06-26 |
| Not Yet Recruiting | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | 2026-06-22 |
| Not Yet Recruiting | A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A Myel Myelodysplastic Syndrome | Phase 2 | 2026-06-19 |
| Not Yet Recruiting | Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Da Core Binding Factor Acute Myeloid Leukemia | Phase 2 | 2026-06-18 |
| Not Yet Recruiting | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell L Lung Non-Small Cell Carcinoma | Phase 3 | 2026-06-05 |
| Not Yet Recruiting | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Cl Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | 2026-06-04 |
| Not Yet Recruiting | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | 2026-05-29 |
| Not Yet Recruiting | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | 2026-05-27 |
| Not Yet Recruiting | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatm Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | 2026-04-29 |
| Suspended | Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysp Refractory Myelodysplastic Syndrome | Phase 1 | 2026-04-27 |
| Recruiting | Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia Fanconi Anemia | — | 2026-04-22 |
| Not Yet Recruiting | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigen Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma | Phase 1 / Phase 2 | 2026-04-22 |
| Not Yet Recruiting | CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adult Acute Lymphoblastic Leukemia, B-All | Phase 2 | 2026-04-22 |
| Recruiting | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic | Phase 1 | 2026-04-22 |
| Enrolling By Invitation | Natural History Study of Early Life Exposures in Agriculture (ELEA) Prostate Cancer, Leukemia, Breast Cancer | — | 2026-04-22 |
| Not Yet Recruiting | Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cance Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Recurrent or Refractory | Phase 1 | 2026-04-22 |
| Not Yet Recruiting | Clinical Genetics Branch Eligibility Screening Survey Melanoma, Li-Fraumeni Syndrome, Pulmonary Blastoma | — | 2026-04-22 |
| Recruiting | NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry fo Very Rare Tumors, Very Rare Cancers, Other Solid Tumors | — | 2026-04-22 |
| Recruiting | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2026-04-22 |
| Suspended | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | 2026-04-22 |
| Not Yet Recruiting | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event Cytokine Release Syndrome, Neoplasms, Lymphoma | N/A | 2026-04-22 |
| Not Yet Recruiting | Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previ Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma | Phase 1 / Phase 2 | 2026-04-22 |
| Not Yet Recruiting | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia | Phase 2 | 2026-04-22 |
| Suspended | Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2026-04-22 |
| Recruiting | Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Car Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC), Recurrent Abdominal Adrenocortical Carcinoma (ACC) | Phase 1 | 2026-04-22 |
| Recruiting | A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine | Phase 2 | 2026-04-22 |
| Recruiting | A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Manage B-All, Acute Lymphoblastic Leukemia | N/A | 2026-04-22 |
| Suspended | Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve O Acute Myeloid Leukemia | Phase 1 | 2026-04-21 |
| Recruiting | Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With Kaposi Sarcoma | Phase 2 | 2026-04-08 |
| Withdrawn | Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer Cancer, Patients Living With Stage IV or Recurrent Cancer | — | 2026-04-07 |
| Recruiting | An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis Colorectal Carcinoma, Familial Adenomatous Polyposis | Phase 2 | 2026-03-31 |
| Recruiting | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | 2026-03-26 |
| Recruiting | Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened I Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 2 | 2026-03-23 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) fo Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | 2026-03-18 |
| Withdrawn | Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma | Phase 2 | 2026-03-16 |
| Recruiting | Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients U Leukemia, Lymphoma, Hematologic Malignancy | — | 2026-03-04 |
| Not Yet Recruiting | Testing the SurVaxM Vaccine for Lung Cancer Prevention Lung Carcinoma | Phase 2 | 2026-02-25 |
| Recruiting | A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer ( Breast Cancer, Breast Carcinoma, Cancer of the Breast | N/A | 2026-02-23 |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma | Phase 2 | 2026-02-22 |
| Recruiting | A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Neurofibromatosis Type 1 | N/A | 2026-02-18 |
| Withdrawn | CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 2 | 2026-02-17 |
| Recruiting | Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors Recurrent CNS Tumors, Brain Cancer, Gliomas | N/A | 2026-02-04 |
| Recruiting | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Comb Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | 2026-01-27 |
| Recruiting | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors | Phase 2 | 2026-01-20 |
| Recruiting | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Tr Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 3 | 2025-12-02 |
| Recruiting | Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks M Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 | Phase 2 | 2025-11-25 |
| Recruiting | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) Cervical Carcinoma, Human Papillomavirus Infection | N/A | 2025-11-24 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 1 / Phase 2 | 2025-11-17 |
| Recruiting | Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide- Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | 2025-11-14 |
| Recruiting | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Mai Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma | Phase 3 | 2025-11-05 |
| Recruiting | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer | Phase 1 | 2025-11-04 |
| Withdrawn | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma | Phase 1 / Phase 2 | 2025-10-31 |
| Recruiting | Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Rela Neuroblastoma | Phase 1 | 2025-10-21 |
| Recruiting | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | Phase 2 | 2025-10-07 |
| Recruiting | Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis | Phase 1 | 2025-10-06 |
| Recruiting | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | 2025-09-29 |
| Recruiting | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Ce Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck | Phase 2 | 2025-09-24 |
| Recruiting | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdo Rhabdomyosarcoma | Phase 1 | 2025-09-22 |
| Withdrawn | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Gastrointestinal Carcinoma, Pancreatic Cancer, Hepatocellular Cancer | Phase 2 | 2025-09-09 |
| Recruiting | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma | Phase 2 | 2025-09-09 |
| Withdrawn | A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants W Colorectal Cancer, Gastroesophageal Cancer | Phase 2 | 2025-09-09 |
| Recruiting | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrin Head and Neck Tumors, Kidney Cancers, Small Cell Lung Cancers | Phase 1 | 2025-08-19 |
| Recruiting | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients Wi Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | 2025-08-15 |
| Withdrawn | Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Me Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer | Phase 2 | 2025-08-15 |
| Recruiting | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia | Phase 2 | 2025-08-14 |
| Active Not Recruiting | Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients W Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 | Phase 3 | 2025-08-07 |
| Withdrawn | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Tre Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 1 | 2025-08-04 |
| Suspended | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblasto Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant | Phase 1 | 2025-07-30 |
| Recruiting | Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ | Phase 2 | 2025-07-28 |
| Recruiting | Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia | — | 2025-07-24 |
| Withdrawn | Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors Neoplasms | Phase 1 | 2025-07-15 |
| Withdrawn | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamo Sinonasal Cancer, Squamous Non-small Cell Lung Cancer, Lung Cancer | Phase 1 / Phase 2 | 2025-07-09 |
| Recruiting | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumo Mesothelioma, Neoplasms, Stomach Neoplasms | Phase 1 | 2025-07-08 |
| Recruiting | Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers Metastatic Malignant Solid Neoplasm | Phase 1 | 2025-07-01 |
| Recruiting | Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Mali Lymphoma, Leukemia | — | 2025-06-23 |
| Recruiting | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLF Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8 | Phase 1 | 2025-06-23 |
| Recruiting | The Vanguard Study: Testing a New Way to Screen for Cancer Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma | N/A | 2025-06-16 |
| Recruiting | Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher Myelodysplastic Syndrome | Phase 2 | 2025-06-12 |
| Terminated | Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma | Phase 2 | 2025-06-09 |
| Completed | Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syn Li-Fraumeni Syndrome | — | 2025-06-05 |
| Recruiting | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to t Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | 2025-06-05 |
| Recruiting | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chem Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8 | Phase 2 | 2025-06-03 |
| Recruiting | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Child B Acute Lymphoblastic Leukemia | Phase 2 | 2025-05-30 |
| Recruiting | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change ( Acute Myeloid Leukemia | Phase 2 | 2025-05-16 |
| Recruiting | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 1 | 2025-05-05 |
| Withdrawn | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients Wit Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | 2025-04-30 |
| Recruiting | Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofi Neurofibromatosis Type 1, Neurofibroma | — | 2025-04-29 |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8 | Phase 1 | 2025-04-18 |
| Recruiting | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Dur Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | 2025-04-08 |
| Recruiting | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-S Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 | Phase 3 | 2025-04-01 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma | Phase 3 | 2025-03-27 |
| Recruiting | Studying TAK-243 in Patients With Advanced Cancer Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Indolent Non-Hodgkin Lymphoma | Phase 1 | 2025-03-24 |
| Recruiting | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | 2025-03-18 |
| Recruiting | Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease an KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease | Phase 2 | 2025-03-17 |
| Recruiting | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes W Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | 2025-03-12 |
| Recruiting | Testing RG1-VLP Vaccine to Prevent HPV-related Cancers Human Papillomavirus-Related Carcinoma | Phase 1 | 2025-02-27 |
| Recruiting | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma | Phase 3 | 2025-02-18 |
| Recruiting | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma | Phase 1 / Phase 2 | 2025-02-07 |
| Recruiting | Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in P Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 1 | 2025-02-03 |
| Recruiting | Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azac Acute Myeloid Leukemia | Phase 1 | 2024-12-18 |
| Recruiting | Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant | Phase 2 | 2024-12-16 |
| Recruiting | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | 2024-12-06 |
| Suspended | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatme Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | 2024-11-08 |
| Suspended | Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Ref Sarcoma, Ewing, Rhabdomyosarcoma | Phase 1 / Phase 2 | 2024-10-31 |
| Recruiting | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | 2024-10-23 |
| Recruiting | Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tu Neurofibromatosis 1, Nerve Sheath Neoplasms | — | 2024-10-09 |
| Recruiting | Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma Astrocytoma, Glioma, Recurrent Glioblastoma | Phase 1 | 2024-10-01 |
| Recruiting | Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma | Phase 2 | 2024-09-27 |
| Recruiting | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A Myelo Acute Myeloid Leukemia | Phase 2 | 2024-09-27 |
| Recruiting | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | 2024-09-25 |
| Recruiting | Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hype Hyperaldosteronism, Hypercortisolism, Cushing s Syndrome | Phase 2 | 2024-09-23 |
| Active Not Recruiting | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) Cervical Carcinoma, Human Papillomavirus Infection | N/A | 2024-09-13 |
| Terminated | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positiv Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma | Phase 2 | 2024-09-13 |
| Recruiting | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Acute Myeloid Leukemia | Phase 2 | 2024-09-13 |
| Recruiting | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostat Prostate Adenocarcinoma | Phase 2 | 2024-09-12 |
| Recruiting | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Po Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Phase 3 | 2024-09-11 |
| Active Not Recruiting | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) Cervical Carcinoma, Human Papillomavirus Infection | N/A | 2024-09-11 |
| Recruiting | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | 2024-09-03 |
| Recruiting | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma Multiple Myeloma | Phase 2 | 2024-08-27 |
| Recruiting | Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk f Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ | Phase 2 | 2024-08-23 |
| Recruiting | Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8 | Phase 1 | 2024-08-14 |
| Withdrawn | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemi T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | 2024-08-09 |
| Withdrawn | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as A Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm | Phase 1 / Phase 2 | 2024-08-02 |
| Recruiting | Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell Carcinoma of the Bladder, Small Cell Carcinoma of the Urinary Tract, Squamous Cell Carcinoma of the Bladder | Phase 2 | 2024-08-01 |
| Recruiting | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumo Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | 2024-08-01 |
| Recruiting | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 / Phase 2 | 2024-07-24 |
| Active Not Recruiting | Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment ( Multiple Myeloma | Phase 2 | 2024-07-23 |
| Recruiting | Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung C Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 | Phase 3 | 2024-07-19 |
| Recruiting | Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurre Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | 2024-07-15 |
| Recruiting | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castle Lymphoma, Primary Effusion | Phase 2 | 2024-07-10 |
| Recruiting | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Imp Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | 2024-07-10 |
| Recruiting | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) Cervical Carcinoma, Human Papillomavirus Infection | N/A | 2024-06-26 |
| Recruiting | A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | 2024-06-25 |
| Recruiting | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | 2024-06-24 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin a Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation | Phase 1 | 2024-06-20 |
| Recruiting | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Tr Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | 2024-06-18 |
| Recruiting | A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine | Phase 1 | 2024-06-17 |
| Recruiting | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract | Phase 2 | 2024-06-13 |
| Recruiting | Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | 2024-06-12 |
| Recruiting | Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses | Phase 2 | 2024-06-10 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | 2024-06-07 |
| Recruiting | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encor Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1 | 2024-06-05 |
| Withdrawn | Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease, Lung Carcinoma | Phase 2 | 2024-06-01 |
| Active Not Recruiting | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and E Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma | Phase 2 | 2024-05-21 |
| Recruiting | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Trea Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | 2024-05-20 |
| Active Not Recruiting | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer | Phase 1 | 2024-05-16 |
| Recruiting | Natural History Study of Kaposi Sarcoma Kaposi Sarcoma, HIV | — | 2024-05-15 |
| Recruiting | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium | Phase 1 / Phase 2 | 2024-05-14 |
| Recruiting | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct | Phase 1 / Phase 2 | 2024-05-08 |
| Recruiting | Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Soli Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm | Phase 2 | 2024-05-07 |
| Suspended | Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adul Sickle Cell Disease, Sickle Cell Anemia, Insomnia | N/A | 2024-05-03 |
| Recruiting | Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) | Phase 1 / Phase 2 | 2024-04-24 |
| Recruiting | Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Ther Prostate Cancer, Recurrent Prostate Cancer, PET Positive | Phase 2 | 2024-04-22 |
| Recruiting | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 3 | 2024-04-19 |
| Recruiting | Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Advanced Non Small Cell Lung Cancer | Phase 1 | 2024-04-18 |
| Withdrawn | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castr Castration Resistant Prostate Cancer | Phase 2 | 2024-04-01 |
| Recruiting | A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Ce Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis | Phase 2 | 2024-03-28 |
| Recruiting | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Ag Metastatic Colorectal Cancer | Phase 1 / Phase 2 | 2024-03-26 |
| Recruiting | 18F-Fluciclovine PET/CT in Multiple Myeloma Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 2 | 2024-03-25 |
| Terminated | Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy Prostate Specific Antigens, Positive Digital Rectal Examination, Strong Family History of Prostate Cancer | — | 2024-03-20 |
| Withdrawn | Non-Viral TCR Gene Therapy Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer | Phase 2 | 2024-03-08 |
| Withdrawn | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Tre Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | 2024-03-05 |
| Recruiting | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma, Metastatic Sinonasal Adenocarcinoma | Phase 2 | 2024-03-04 |
| Recruiting | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Me Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8 | Phase 2 | 2024-02-19 |
| Recruiting | Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer Urinary Urge Incontinence, Stress Urinary Incontinence, Prostatic Hyperplasia | Phase 2 | 2024-02-15 |
| Active Not Recruiting | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A Co Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | 2024-02-09 |
| Active Not Recruiting | Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Re Adult Ovarian Granulosa Cell Tumor | Phase 2 | 2024-02-08 |
| Recruiting | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposert Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Myxofibrosarcoma | Phase 1 | 2024-02-06 |
| Recruiting | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Sur Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | 2024-02-02 |
| Suspended | Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma | Phase 2 | 2024-01-31 |
| Withdrawn | Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytor Malignant Pleural Mesotheliomas (Mpm), Malignant Pleural Effusions (Mpe), Epithelial Tumors, Malignant | Phase 1 | 2024-01-31 |
| Recruiting | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications Glioma, Medulloblastoma, Ependymoma | Phase 1 / Phase 2 | 2024-01-31 |
| Recruiting | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Ly Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma | Phase 2 | 2024-01-23 |
| Recruiting | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectab Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1 | Phase 2 | 2024-01-12 |
| Recruiting | Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility S Neurofibromatosis 1, Noonan Syndrome, Legius Syndrome | N/A | 2024-01-10 |
| Recruiting | Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatmen Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma | Phase 2 | 2024-01-04 |
| Recruiting | Obeticholic Acid for Prevention in Barrett's Esophagus Barrett Esophagus, Esophageal Adenocarcinoma | Phase 2 | 2024-01-03 |
| Recruiting | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Pr Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Phase 2 | 2023-12-27 |
| Recruiting | Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies | Phase 1 | 2023-12-19 |
| Recruiting | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovaria Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma | Phase 1 | 2023-12-18 |
| Terminated | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma Pancreatic Acinar Cell Carcinoma | Phase 2 | 2023-12-14 |
| Active Not Recruiting | Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma | Phase 2 | 2023-12-13 |
| Active Not Recruiting | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastr Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8 | Phase 2 | 2023-12-06 |
| Active Not Recruiting | Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm | Phase 2 | 2023-12-04 |
| Active Not Recruiting | Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GA GATA2, Immunodeficiency | Phase 2 | 2023-11-29 |
| Recruiting | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclopho Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma | Phase 3 | 2023-11-27 |
| Recruiting | Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer Prostate Cancer | N/A | 2023-11-20 |
| Terminated | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2023-11-14 |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8 | Phase 1 | 2023-11-08 |
| Active Not Recruiting | Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subj Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 2 | 2023-11-07 |
| Withdrawn | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | 2023-10-23 |
| Recruiting | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | 2023-10-19 |
| Active Not Recruiting | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma | Phase 2 | 2023-10-16 |
| Withdrawn | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N Bladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | 2023-10-12 |
| Active Not Recruiting | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome | Phase 1 | 2023-10-10 |
| Recruiting | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effective Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm | Phase 1 / Phase 2 | 2023-09-28 |
| Withdrawn | Omics of Cancer: OncoGenomics Neoplasms, Cancer | — | 2023-09-27 |
| Active Not Recruiting | Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare C Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm | Phase 2 | 2023-09-26 |
| Recruiting | Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 | 2023-09-25 |
| Suspended | Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Trea Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 2 | 2023-09-22 |
| Active Not Recruiting | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma | Phase 1 | 2023-09-14 |
| Active Not Recruiting | Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment Metastatic Neuroendocrine Tumor | Phase 2 | 2023-08-30 |
| Active Not Recruiting | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancie Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell | Phase 1 | 2023-08-28 |
| Completed | Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute Leukemias B Cell, Acute Lymphoblastic Leukemia, Relapsed/Refractory | — | 2023-08-25 |
| Recruiting | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Ad Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | 2023-08-10 |
| Withdrawn | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in T Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | 2023-08-10 |
| Active Not Recruiting | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) Respiratory Tract Diseases, Neoplasms, Neoplasms by Histologic Type | Phase 2 | 2023-08-02 |
| Suspended | The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN) Melanoma | N/A | 2023-07-25 |
| Active Not Recruiting | Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | 2023-07-20 |
| Active Not Recruiting | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMA Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | 2023-07-14 |
| Recruiting | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alteratio Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | 2023-07-06 |
| Recruiting | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | 2023-06-27 |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodys Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts | Phase 2 | 2023-06-27 |
| Completed | Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastr Gastric Cancer, Gastric Neoplasms, Gastric Adenocarcinoma | Phase 2 | 2023-06-22 |
| Recruiting | CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | 2023-06-12 |
| Recruiting | A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combinatio Cancer Of Prostate | Phase 2 | 2023-06-12 |
| Withdrawn | Vaccine Response With NT-I7 Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma | Phase 1 | 2023-05-30 |
| Recruiting | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advan Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8 | Phase 1 | 2023-05-22 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma | Phase 1 | 2023-05-18 |
| Recruiting | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 Brain Tumor, Cancer | Phase 1 / Phase 2 | 2023-05-16 |
| Enrolling By Invitation | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenviron Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer | — | 2023-05-15 |
| Recruiting | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | 2023-05-11 |
| Active Not Recruiting | Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome | Phase 2 | 2023-05-08 |
| Recruiting | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | 2023-04-25 |
| Active Not Recruiting | Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis Glioma | Phase 1 | 2023-04-07 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | 2023-04-07 |
| Completed | Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Lymphoma, Non-Hodgkin Lymphoma, NHL | Phase 1 / Phase 2 | 2023-04-05 |
| Active Not Recruiting | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | 2023-03-31 |
| Active Not Recruiting | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Phase 2 / Phase 3 | 2023-03-30 |
| Active Not Recruiting | Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 T Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | 2023-03-24 |
| Recruiting | Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia Fanconi Anemia, Inherited Bone Marrow Failure Syndrome | — | 2023-03-23 |
| Recruiting | Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL Prostate Cancer, Biochemically Recurrent | — | 2023-03-21 |
| Suspended | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma | Phase 1 / Phase 2 | 2023-03-20 |
| Active Not Recruiting | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 2 / Phase 3 | 2023-03-13 |
| Recruiting | Rare Tumors and Cancer Predisposition in Individuals and Families Cancer, Hereditary Neoplasms, Genetic Predisposition to Cancer | — | 2023-03-10 |
| Recruiting | Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease Graft vs Host Disease | Phase 1 / Phase 2 | 2023-03-06 |
| Recruiting | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosa High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma | Phase 2 / Phase 3 | 2023-03-03 |
| Active Not Recruiting | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Follicular Lymphoma | Phase 1 | 2023-03-01 |
| Recruiting | A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme Immunodeficiency, Hematopoietic Stem Cell Transplantation | Phase 2 | 2023-02-23 |
| Recruiting | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendoc Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm | Phase 2 | 2023-02-03 |
| Recruiting | Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplant HIV, Hematologic Malignancies | Phase 1 / Phase 2 | 2023-01-26 |
| Suspended | Testing Obeticholic Acid for Familial Adenomatous Polyposis Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma | Phase 2 | 2023-01-19 |
| Terminated | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 | 2023-01-18 |
| Recruiting | Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Myelodysplastic Syndromes | — | 2023-01-11 |
| Recruiting | Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption HIV | Phase 2 | 2023-01-09 |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia | Phase 1 / Phase 2 | 2022-12-28 |
| Recruiting | Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplati Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | 2022-12-15 |
| Active Not Recruiting | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezol Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer | Phase 2 | 2022-12-07 |
| Recruiting | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | 2022-12-06 |
| Terminated | BMS-986253 in Myelodysplastic Syndromes Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2022-11-29 |
| Terminated | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8 | Phase 2 | 2022-11-22 |
| Recruiting | The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycopheno Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | 2022-11-18 |
| Recruiting | Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patie Prostate Cancer | N/A | 2022-11-18 |
| Active Not Recruiting | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma | Phase 1 / Phase 2 | 2022-11-17 |
| Recruiting | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma | Phase 1 / Phase 2 | 2022-11-16 |
| Recruiting | Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study i Hematopoietic Stem Cell Transplantation | N/A | 2022-11-16 |
| Recruiting | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Se Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | 2022-11-16 |
| Recruiting | Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advance Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 2 | 2022-11-14 |
| Active Not Recruiting | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients Colorectal Carcinoma, Lynch Syndrome | Phase 1 / Phase 2 | 2022-11-10 |
| Terminated | Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | 2022-11-08 |
| Recruiting | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma | Phase 1 | 2022-11-03 |
| Withdrawn | Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma | Phase 1 | 2022-11-03 |
| Active Not Recruiting | Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smolderi Multiple Myeloma | Phase 2 | 2022-10-31 |
| Recruiting | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies Urothelial Cancer, Bladder Cancer, Genitourinary Cancer | — | 2022-10-24 |
| Recruiting | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metast Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer | Phase 2 | 2022-10-24 |
| Active Not Recruiting | Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colo Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis | Phase 2 | 2022-10-13 |
| Suspended | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | 2022-10-07 |
| Suspended | Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | 2022-10-05 |
| Recruiting | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms | Phase 1 / Phase 2 | 2022-10-03 |
| Recruiting | Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of To Cigarette Smoking-Related Carcinoma | Phase 2 | 2022-09-21 |
| Recruiting | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | 2022-09-19 |
| Active Not Recruiting | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | 2022-09-08 |
| Recruiting | 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy Localized Prostate Cancer | Phase 2 | 2022-08-31 |
| Completed | Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19 COVID-19 | — | 2022-08-30 |
| Recruiting | Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma | Phase 2 | 2022-08-29 |
| Active Not Recruiting | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia | Phase 2 | 2022-08-24 |
| Recruiting | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma | Phase 2 | 2022-08-18 |
| Recruiting | Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS Myelodysplastic Syndromes | — | 2022-08-18 |
| Recruiting | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Anal Melanoma, Bladder Melanoma, Cervical Melanoma | Phase 2 | 2022-08-11 |
| Active Not Recruiting | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma | Phase 2 | 2022-08-09 |
| Recruiting | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Cha Recurrent AL Amyloidosis, Refractory AL Amyloidosis | Phase 1 | 2022-08-03 |
| Suspended | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | 2022-08-02 |
| Active Not Recruiting | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma | Phase 1 | 2022-07-27 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | 2022-07-26 |
| Active Not Recruiting | Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8 | Phase 2 | 2022-07-19 |
| Recruiting | Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatmen Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | Phase 1 / Phase 2 | 2022-07-13 |
| Active Not Recruiting | Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | Phase 2 | 2022-07-11 |
| Active Not Recruiting | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma | Phase 1 | 2022-07-07 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 1 | 2022-07-06 |
| Withdrawn | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma | Phase 2 | 2022-06-30 |
| Recruiting | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma | Phase 2 / Phase 3 | 2022-06-28 |
| Completed | Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity | Phase 2 | 2022-06-21 |
| Recruiting | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 2 | 2022-06-10 |
| Active Not Recruiting | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 3 | 2022-06-03 |
| Recruiting | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 2 | 2022-06-02 |
| Recruiting | A Natural History Study of Children and Adults With Olfactory Neuroblastoma Olfactory Neuroblastoma, Esthesioneuroblastoma | — | 2022-06-02 |
| Recruiting | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontin Malignant Glioma | Phase 1 / Phase 2 | 2022-05-31 |
| Recruiting | Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malign Hematologic Neoplasms | Phase 1 / Phase 2 | 2022-05-23 |
| Recruiting | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia Hairy Cell Leukemia, Hairy Cell Leukemia Variant | Phase 1 | 2022-05-23 |
| Recruiting | Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carci Neuroendocrine Tumors, Carcinoma, Neuroendocrine | — | 2022-04-25 |
| Recruiting | Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies Costello Syndrome, Noonan Syndrome, Cardiofaciocutaneous Syndrome | — | 2022-04-25 |
| Active Not Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involv Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS | Phase 1 | 2022-04-19 |
| Recruiting | PT-112 in Subjects With Thymoma and Thymic Carcinoma Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer | Phase 2 | 2022-04-06 |
| Terminated | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma | Phase 1 | 2022-03-24 |
| Recruiting | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Peritoneal Malignant Mesothelioma | Phase 2 | 2022-03-22 |
| Active Not Recruiting | Pomalidomide Treatment in Patients With Kaposi Sarcoma Skin Kaposi Sarcoma | Phase 2 | 2022-03-18 |
| Active Not Recruiting | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recur Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma | Phase 2 | 2022-03-11 |
| Terminated | T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | 2022-03-08 |
| Completed | Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) Adenosquamous Carcinoma of the Pancreas | Phase 2 | 2022-03-07 |
| Recruiting | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy | Phase 1 / Phase 2 | 2022-03-04 |
| Active Not Recruiting | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRIS Human Papillomavirus-Related Cervical Carcinoma | Phase 4 | 2022-03-01 |
| Withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ an Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma | Phase 2 | 2022-02-22 |
| Completed | Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myelom Multiple Myeloma | Phase 3 | 2022-02-16 |
| Terminated | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms | Phase 2 | 2022-02-15 |
| Active Not Recruiting | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloi Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2022-02-10 |
| Active Not Recruiting | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at th Endometrial Serous Adenocarcinoma | EARLY_Phase 1 | 2022-02-08 |
| Active Not Recruiting | Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8 | Phase 2 | 2022-02-08 |
| Suspended | Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 1 | 2022-02-02 |
| Suspended | Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Youn Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma | Phase 1 | 2022-01-25 |
| Recruiting | Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Ritu Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia | Phase 2 | 2022-01-05 |
| Enrolling By Invitation | Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies Breast Cancer, Ovarian Cancer, Uterine Cancer | — | 2022-01-04 |
| Active Not Recruiting | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma | Phase 1 / Phase 2 | 2021-12-22 |
| Active Not Recruiting | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cance Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma | Phase 1 | 2021-12-20 |
| Terminated | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patient Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma | Phase 2 | 2021-12-18 |
| Completed | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma | Phase 1 | 2021-12-16 |
| Active Not Recruiting | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or With Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma | Phase 2 | 2021-12-15 |
| Active Not Recruiting | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recur Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC | Phase 2 | 2021-12-14 |
| Withdrawn | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patie Sarcomas, Melanomas, Germ Cell Tumors | Phase 1 / Phase 2 | 2021-12-14 |
| Recruiting | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas | Phase 1 | 2021-12-10 |
| Recruiting | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma | Phase 1 | 2021-12-08 |
| Completed | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Glioblastoma, Gliosarcoma, Malignant Glioma | Phase 2 | 2021-12-08 |
| Recruiting | Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neu Neurofibromatosis 1 | Phase 1 / Phase 2 | 2021-11-29 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma | Phase 1 | 2021-11-22 |
| Recruiting | Natural History of KSHV-Associated Multicentric Castleman s Disease Multicentric Castleman s Disease | — | 2021-11-17 |
| Recruiting | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Uppe Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 / Phase 3 | 2021-11-12 |
| Active Not Recruiting | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | 2021-10-21 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumor Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma | Phase 1 | 2021-10-20 |
| Recruiting | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosi Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer | Phase 1 | 2021-10-19 |
| Active Not Recruiting | A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment i Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 2 | 2021-10-15 |
| Completed | CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicit Leukemia, Acute Lymphoblastic, Lymphoblastic Leukemia, Acute, Childhood | — | 2021-10-14 |
| Active Not Recruiting | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Sm Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus | Phase 1 / Phase 2 | 2021-10-05 |
| Active Not Recruiting | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-C Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | 2021-10-05 |
| Recruiting | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma Kaposi Sarcoma | Phase 1 / Phase 2 | 2021-09-29 |
| Recruiting | Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Hematologic Neoplasms | Phase 1 / Phase 2 | 2021-09-23 |
| Recruiting | A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small HRD Cancer, SCLC, Advanced Solid Tumors | Phase 1 / Phase 2 | 2021-09-20 |
| Recruiting | Precision-Based Genomics in Prostate Cancer Prostate Cancer | — | 2021-09-14 |
| Withdrawn | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiat Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 | Phase 2 | 2021-09-09 |
| Completed | Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Bio Dyskeratosis Congenita, Telomere Biology Disorders | — | 2021-09-09 |
| Completed | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or R High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma | Phase 1 | 2021-08-31 |
| Suspended | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("E Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma | Phase 1 | 2021-08-31 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma | Phase 1 | 2021-08-25 |
| Active Not Recruiting | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 1 / Phase 2 | 2021-08-19 |
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Advanced Colorectal Carcinoma, Advanced Digestive System Carcinoma, Advanced Gastric Carcinoma | Phase 1 | 2021-08-13 |
| Completed | Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor Depression | N/A | 2021-08-11 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma | Phase 1 | 2021-08-09 |
| Active Not Recruiting | National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma | — | 2021-07-28 |
| Recruiting | Connect for Cancer Prevention Study (Connect) Cancer, General Research Use | — | 2021-07-26 |
| Active Not Recruiting | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Rem Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 2 | 2021-07-23 |
| Active Not Recruiting | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutet Neuroendocrine Neoplasm | Phase 1 | 2021-07-22 |
| Recruiting | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Rel Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 1 | 2021-07-09 |
| Terminated | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lun EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine | Phase 2 | 2021-07-07 |
| Recruiting | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 1 | 2021-07-02 |
| Completed | Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients Sleep Circadian Rhythms, Chronodisruption | — | 2021-06-29 |
| Active Not Recruiting | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastat Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma | Phase 3 | 2021-06-28 |
| Recruiting | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma | Phase 2 | 2021-06-22 |
| Terminated | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms | Phase 1 / Phase 2 | 2021-06-15 |
| Terminated | Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma Mesothelioma | Phase 1 | 2021-06-11 |
| Active Not Recruiting | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma | Phase 2 | 2021-06-10 |
| Active Not Recruiting | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Ca SCLC, Small Cell Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | 2021-06-01 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma | Phase 1 | 2021-06-01 |
| Recruiting | Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | Phase 1 | 2021-05-24 |
| Recruiting | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Pl Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm | Phase 1 | 2021-05-21 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and P Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | 2021-05-20 |
| Suspended | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diag Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | 2021-05-20 |
| Completed | Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects Neurofibromatosis 1 | — | 2021-05-12 |
| Completed | Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Chronic GVHD | Phase 2 | 2021-05-10 |
| Completed | Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 Familial Adenomatous Polyposis | — | 2021-05-07 |
| Terminated | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) Breast Cancer, Triple Negative Breast Cancer, HER2+ Breast Cancer | Phase 1 | 2021-05-04 |
| Active Not Recruiting | Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | 2021-05-03 |
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | 2021-05-03 |
| Completed | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Solid Tumor Malignancy, Hematologic Malignancy, Leukemia | Phase 2 | 2021-04-28 |
| Completed | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain | Phase 1 | 2021-04-27 |
| Recruiting | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treat Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | 2021-04-27 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma | Phase 2 | 2021-04-26 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | 2021-04-14 |
| Recruiting | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 2 | 2021-04-13 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 1 | 2021-04-09 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogam Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome | Phase 1 / Phase 2 | 2021-04-06 |
| Recruiting | Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biops Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS) | — | 2021-03-30 |
| Completed | Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiet Anxiety | Phase 2 | 2021-03-18 |
| Active Not Recruiting | A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Du Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 2 | 2021-03-17 |
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Ne Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma | Phase 2 | 2021-03-17 |
| Terminated | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) Locally Advanced Rectal Carcinoma, Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Phase 1 | 2021-03-17 |
| Active Not Recruiting | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subj Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | 2021-03-10 |
| Suspended | Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | 2021-03-08 |
| Recruiting | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Le Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2021-03-02 |
| Active Not Recruiting | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | 2021-03-01 |
| Completed | Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosi Neurofibromatosis 1, Peripheral Nerve Neoplasms, Malignant | — | 2021-02-24 |
| Recruiting | A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive a Cancer Of Prostate, Prostate Neoplasms | Phase 1 / Phase 2 | 2021-02-23 |
| Active Not Recruiting | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | 2021-02-22 |
| Active Not Recruiting | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Mye Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | 2021-02-17 |
| Active Not Recruiting | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Mye Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | 2021-02-16 |
| Active Not Recruiting | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients Wi Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma | Phase 3 | 2021-02-16 |
| Active Not Recruiting | NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 Data Cancer, Mortality, Chronic Diseases | — | 2021-02-09 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 | 2021-02-04 |
| Active Not Recruiting | Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma | — | 2021-02-04 |
| Withdrawn | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome | Phase 1 | 2021-01-28 |
| Withdrawn | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutat Metastatic HPV-16 Positive Squamous Cell Anal Cancer | Phase 2 | 2021-01-27 |
| Active Not Recruiting | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnos B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | 2021-01-25 |
| Terminated | E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer Uterine Cervical Neoplasms | EARLY_Phase 1 | 2021-01-14 |
| Active Not Recruiting | Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8 | Phase 2 | 2021-01-13 |
| Recruiting | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | 2021-01-11 |
| Recruiting | Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive S Extensive Stage Lung Small Cell Carcinoma | Phase 2 / Phase 3 | 2021-01-07 |
| Recruiting | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant Hairy Cell Leukemia | Phase 2 | 2021-01-07 |
| Recruiting | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | 2020-12-28 |
| Active Not Recruiting | Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer | Phase 2 | 2020-12-26 |
| Active Not Recruiting | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype | Phase 2 | 2020-12-24 |
| Recruiting | Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis Gastric Cancer, Gastric Neoplasm, Gastrointestinal Stromal Sarcoma | — | 2020-12-18 |
| Completed | Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Mali Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma | Phase 1 | 2020-12-17 |
| Recruiting | A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | 2020-12-17 |
| Terminated | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Ci Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma | Phase 3 | 2020-12-09 |
| Completed | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX- Metastatic Cancer, Solid Tumors | Phase 1 / Phase 2 | 2020-11-24 |
| Terminated | Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s Neuroendocrine Tumors, Carcinoma, Neuroendocrine | — | 2020-11-24 |
| Completed | Mobile Sensor Technologies to Assess General Symptomology of People With Cancer Neoplasms, Solid Tumors, Prostate Cancer | — | 2020-11-23 |
| Active Not Recruiting | EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Metastatic Anal Squamous Cell Carcinoma | Phase 3 | 2020-11-17 |
| Active Not Recruiting | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gast Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8 | Phase 2 | 2020-11-16 |
| Active Not Recruiting | National Cancer Institute "Cancer Moonshot Biobank" Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | — | 2020-11-11 |
| Active Not Recruiting | Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma | Phase 2 | 2020-11-04 |
| Suspended | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Gen Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma | Phase 2 | 2020-11-03 |
| Recruiting | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL Hairy Cell Leukemia | Phase 2 | 2020-10-28 |
| Completed | Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Ca Cancer, Neoplasms, Solid Tumors | — | 2020-10-27 |
| Recruiting | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor | Phase 1 | 2020-10-27 |
| Active Not Recruiting | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-s Leptomeningeal Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 1 | 2020-10-26 |
| Terminated | A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothel Urothelial Cancer | Phase 2 | 2020-10-26 |
| Recruiting | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes | Phase 1 / Phase 2 | 2020-10-14 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma | Phase 2 | 2020-10-13 |
| Active Not Recruiting | Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma | Phase 2 | 2020-10-05 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemo Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma | Phase 1 | 2020-09-24 |
| Active Not Recruiting | Radium-223 in Biochemically Recurrent Prostate Cancer Biochemical Recurrent Prostate Cancer | Phase 2 | 2020-09-22 |
| Completed | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers Small Bowel Cancers, Colorectal Cancers | Phase 2 | 2020-09-22 |
| Recruiting | Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases | Phase 2 | 2020-09-22 |
| Withdrawn | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cispla Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | Phase 1 / Phase 2 | 2020-09-18 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma | Phase 1 | 2020-09-18 |
| Recruiting | En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resecto Bladder Cancer | — | 2020-09-09 |
| Active Not Recruiting | Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma | Phase 2 | 2020-09-08 |
| Active Not Recruiting | Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies Prostate Cancer | — | 2020-09-02 |
| Active Not Recruiting | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | 2020-09-01 |
| Completed | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usu Gliosarcoma, MGMT-Unmethylated Glioblastoma | Phase 2 / Phase 3 | 2020-09-01 |
| Recruiting | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Tria Neoplasms | Phase 2 | 2020-08-24 |
| Active Not Recruiting | Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-sma Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8 | Phase 3 | 2020-08-13 |
| Active Not Recruiting | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associ HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer | Phase 1 / Phase 2 | 2020-08-11 |
| Terminated | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Metastatic Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma | Phase 2 | 2020-08-09 |
| Active Not Recruiting | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendo Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm | Phase 2 | 2020-08-06 |
| Active Not Recruiting | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Synd Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | 2020-08-04 |
| Active Not Recruiting | Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | 2020-08-04 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | 2020-07-29 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor | Phase 1 | 2020-07-20 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma | Phase 2 | 2020-07-20 |
| Active Not Recruiting | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Extensive Stage Lung Small Cell Carcinoma | Phase 2 | 2020-07-20 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 / Phase 2 | 2020-07-17 |
| Recruiting | Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) Urothelial Cancer, Bladder Cancer, Genitourinary Cancer | Phase 1 | 2020-07-13 |
| Active Not Recruiting | Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | 2020-07-13 |
| Recruiting | PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma Kaposi Sarcoma | Phase 1 / Phase 2 | 2020-07-13 |
| Active Not Recruiting | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Gl Gliosarcoma, Newly Diagnosed, Glioblastoma | Phase 1 | 2020-07-07 |
| Terminated | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer Papillomavirus Infections, Oropharyngeal Neoplasms | Phase 2 | 2020-07-06 |
| Active Not Recruiting | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Pati Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | 2020-06-30 |
| Terminated | Natural History Study of Children and Adults With Adrenocortical Cancer (ACC) Adrenocortical Carcinoma, Adrenocortical Cancer | — | 2020-06-25 |
| Withdrawn | Testing the Safety of CB-5339 in Patients With Cancer Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Neoplasm | Phase 1 | 2020-06-18 |
| Active Not Recruiting | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cance Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma | Phase 1 | 2020-06-17 |
| Recruiting | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | 2020-06-16 |
| Completed | Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Head and Neck Cancer, Head and Neck Neoplasms | Phase 1 / Phase 2 | 2020-06-09 |
| Active Not Recruiting | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Cervical Cancer, HPV Cancers, Anal Cancer | Phase 1 / Phase 2 | 2020-06-09 |
| Completed | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction | Phase 2 | 2020-06-09 |
| Withdrawn | Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation Hematopoietic Stem Cell Transplantation, Cell Transplantation, Hematologic Malignancies | — | 2020-06-05 |
| Active Not Recruiting | NCI COVID-19 in Cancer Patients, NCCAPS Study COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm | — | 2020-06-05 |
| Recruiting | Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors VHL Pancreatic Neuroendocrine Tumors, Von Hippel-Lindau Disease, Neuroendocrine Tumors | Phase 2 | 2020-06-02 |
| Terminated | Tocilizumab for Patients With Cancer and COVID-19 Disease Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia | Phase 2 | 2020-05-28 |
| Withdrawn | E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia Cervical Intraepithelial Neoplasia | Phase 1 | 2020-05-28 |
Showing the 500 most recent trials.